tiprankstipranks
Trending News
More News >

NeuroScientific Biopharmaceuticals Reports Revenue Growth and Reduced Losses

Story Highlights

Confident Investing Starts Here:

Neuroscientific Biopharmaceuticals Ltd. ( (AU:NSB) ) has provided an update.

NeuroScientific Biopharmaceuticals Limited reported a 5% increase in revenues for the half-year ending December 2024, while significantly reducing its loss by 70% compared to the previous period. Despite not declaring a dividend, the company improved its net tangible assets per share from 2.44 cents to 3.23 cents, indicating a stronger financial position.

More about Neuroscientific Biopharmaceuticals Ltd.

NeuroScientific Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development of therapeutic products targeting neurodegenerative conditions. The company is committed to advancing treatments that address significant unmet medical needs in neurological health.

YTD Price Performance: 26.67%

Average Trading Volume: 173,843

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$5.49M

Learn more about NSB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App